Skip to content
OpenCapital
Get started

MoonLake Immunotherapeutics MLTX Cash ratio

Cash ratio at other companies

Eli Lilly logo
Eli LillyLLY
0.1×0.0×
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
3×-4.2×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
6×+3.7×
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
0.1×0.0×
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
0.5×-0.5×
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
2.3×+0.8×

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.49B-45.9%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Calculated from MoonLake Immunotherapeutics’s reported figures.

cash and equivalents/total current liabilities=6.5×

Based on the most recent quarter.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's cash ratio?
MoonLake Immunotherapeutics (MLTX) reported cash ratio of 6.5× in Q1 2026.
How has MoonLake Immunotherapeutics's cash ratio changed year-over-year?
MoonLake Immunotherapeutics's cash ratio decreased by 42.8% year-over-year, from 11.3× to 6.5×.
What is the long-term trend for MoonLake Immunotherapeutics's cash ratio?
Over 5 years (2020 to 2025), MoonLake Immunotherapeutics's cash ratio has grown at a -6.7% compound annual growth rate (CAGR), from 10.4× to 7.4×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.